TMX Newsfile·2026-02-13 03:53Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. for the period between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the company's drug candidate and its regulatory approval status [1]. Group 1: Lawsuit Details - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline, which led to investors suffering damages when the true information became public [5]. - Investors who purchased uniQure shares during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information. A lead plaintiff must file a motion by April 13, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].